Table 2.
Response | Bevacizumab + Carboplatin (N = 58) | Bevacizumab (N = 62) | P |
---|---|---|---|
Objective response (complete or partial response) | 8 (14%) | 4 (6%) | .18 |
Best response | .23 | ||
Partial response | 8 (14%) | 4 (6%) | |
Stable disease | 36 (62%) | 36 (58%) | |
Progressive disease | 14 (24%) | 22 (35%) |